Perspective Therapeutics reported fourth-quarter earnings showing an EPS loss of 0.29 , matching market expectations. Revenue reached $290,000 , exceeding the forecast of $185,860. The radiopharmaceutical developer continued advancing its clinical pipeline during the quarter. With US markets closed for Christmas, investor response to the results is expected to materialize once trading resumes.